Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent ...

A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of ...

Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing therapies across oncology, immunology, and diabetes and cardiovascular areas.

Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate (ADC) sac-TMT already ...

Add Yahoo as a preferred source to see more of our stories on Google. Illustration shows Merck logo (Reuters) -Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the ...

Add Yahoo as a preferred source to see more of our stories on Google. A wall showing a Merck & Co. logo in Kenilworth, New Jersey (Courtesy of Merck & Co.) This story was originally published on ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

As Merck MRK is gearing up to report its fourth-quarter and full-year 2025 results on Feb. 3, investors' focus is likely to be on the sales performance of its blockbuster cancer drug, Keytruda. The ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its ...

Merck is in discussions with various global health authorities about making its COVID antiviral pill molnupiravir available ...